Table 4.
Direct Comparison of Both MTX-Autoinjectors by All Participants After Cross-Testing
| Parameters | Used MTX-Autoinjector | ||
|---|---|---|---|
| A (n=35) | B (n=65) | ||
| Better audible feedback after completed injection | |||
| A | 86% | 73% | |
| B | 3% | 8% | |
| No preference | 11% | 19% | |
| Most convenient injection system | |||
| A | 77% | 87% | |
| B | 14% | 5% | |
| No preference | 9% | 8% | |
| Easy to self-inject | |||
| A | 71% | 78% | |
| B | 23% | 13% | |
| No preference | 6% | 9% | |
| More intuitive use | |||
| A | 60% | 64% | |
| B | 29% | 13% | |
| No preference | 11% | 23% | |
Notes: Figures are rounded at the nearest unit. Used MTX-autoinjector: A (n=35): the 35 RA patients who currently used MTX-autoinjector A compared MTX-autoinjectors A and B; B (n=65): the 65 RA patients who currently used MTX-autoinjector B compared MTX-autoinjectors A and B. For example: 86% of the 35 patients who currently used MTX-autoinjector A claimed that the audible feedback after completed injection was in favor of MTX-autoinjector A, 3% claimed to prefer MTX-autoinjector B, and 11% had no preference.
Abbreviation: MTX, methotrexate.